1 / 4

Valsartan shows no difference in the composite PEP ( cardiovascular event ) vs amlodipine and mitigate results o

Valsartan shows no difference in the composite PEP ( cardiovascular event ) vs amlodipine and mitigate results on MI and death. Matsushita K et al. The NAGOYA-Heart trial. Late-breaking clinical trial. ACC Annual Scientific session 2011. SUMMARY.

branxton
Download Presentation

Valsartan shows no difference in the composite PEP ( cardiovascular event ) vs amlodipine and mitigate results o

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Valsartan shows no difference in the composite PEP (cardiovascularevent) vs amlodipine and mitigateresults on MI and death Matsushita K et al. The NAGOYA-Heart trial. Late-breaking clinical trial. ACC Annual Scientific session 2011

  2. SUMMARY • The NAGOYA HEART studydid not demonstratesignificantreduction in primary composite end point withvalsartan versus amlodipine in Japanese hypertensive patients. • Among the components of primary end point onlyheartfailurewas more reducedwith ARB. • No reduction in all-cause mortalitywasfoundwith an ARB versus CCB.

More Related